125 related articles for article (PubMed ID: 16763236)
1. EU offers incentives to firms to produce medicines for children.
Watson R
BMJ; 2006 Jun; 332(7554):1352. PubMed ID: 16763236
[No Abstract] [Full Text] [Related]
2. EU agrees deal on cheaper drugs for developing world.
Watson R
BMJ; 2003 Jun; 326(7401):1229. PubMed ID: 12791716
[No Abstract] [Full Text] [Related]
3. Drug development for children: how is pharma tackling an unmet need?
Hawcutt DB; Smyth RL
IDrugs; 2008 Jul; 11(7):502-7. PubMed ID: 18600597
[TBL] [Abstract][Full Text] [Related]
4. Redesigner drugs.
Dove A
Nat Biotechnol; 2004 Aug; 22(8):953-7. PubMed ID: 15286643
[TBL] [Abstract][Full Text] [Related]
5. Financial effects of pharmaceutical price regulation on R&D spending by EU versus US firms.
Golec J; Vernon JA
Pharmacoeconomics; 2010; 28(8):615-28. PubMed ID: 20617857
[TBL] [Abstract][Full Text] [Related]
6. Regulatory watch: Where do new medicines originate from in the EU?
Lincker H; Ziogas C; Carr M; Porta N; Eichler HG
Nat Rev Drug Discov; 2014 Feb; 13(2):92-3. PubMed ID: 24481298
[No Abstract] [Full Text] [Related]
7. European prices of newly launched reimbursable pharmaceuticals--a pilot study.
Martikainen J; Kivi I; Linnosmaa I
Health Policy; 2005 Nov; 74(3):235-46. PubMed ID: 16226136
[TBL] [Abstract][Full Text] [Related]
8. Maximizing exclusivity for drug products.
French H
Nat Rev Drug Discov; 2005 Sep; 4(9):709. PubMed ID: 16178117
[No Abstract] [Full Text] [Related]
9. Cost-effectiveness data on biologics needed.
Sheridan C; Katsnelson A
Nat Biotechnol; 2005 Mar; 23(3):272-3. PubMed ID: 15765069
[No Abstract] [Full Text] [Related]
10. The European value-pricing game.
McGuire A
Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):5-6. PubMed ID: 22280188
[No Abstract] [Full Text] [Related]
11. [The European Union and drugs].
Viala G; Campion MD
Ann Pharm Fr; 1995; 53(4):184-7. PubMed ID: 7574273
[TBL] [Abstract][Full Text] [Related]
12. Biotech patents-business as usual?
Lawrence S
Nat Biotechnol; 2008 Dec; 26(12):1326. PubMed ID: 19060861
[No Abstract] [Full Text] [Related]
13. Developing a European framework for research on children's medicines: an examination of the proposed EU regulation on medicinal products for paediatric use.
Seyberth HW; Demotes-Mainard J; Wrobel P
Pediatr Nephrol; 2005 Nov; 20(11):1537-40. PubMed ID: 16167134
[No Abstract] [Full Text] [Related]
14. Mergers in Japan help firms retain own products.
Fuyuno I
Nat Rev Drug Discov; 2005 May; 4(5):358. PubMed ID: 15902766
[No Abstract] [Full Text] [Related]
15. Transparency of EU medicines agencies.
Kopp C
Prescrire Int; 2003 Aug; 12(66):156. PubMed ID: 12908499
[No Abstract] [Full Text] [Related]
16. Stimulating pharmaceutical innovation in the EU.
Annemans L; Cleemput I; Hulstaert F; Simoens S
Expert Rev Pharmacoecon Outcomes Res; 2011 Jun; 11(3):235-9. PubMed ID: 21671690
[No Abstract] [Full Text] [Related]
17. R&D technology investments: misguided and expensive or a better way to discover medicines?
Schmid EF; Smith DA
Drug Discov Today; 2006 Sep; 11(17-18):775-84. PubMed ID: 16935744
[TBL] [Abstract][Full Text] [Related]
18. Funding pharmaceutical innovation through direct tax credits.
Lybecker KM; Freeman RA
Health Econ Policy Law; 2007 Jul; 2(Pt 3):267-84. PubMed ID: 18634650
[TBL] [Abstract][Full Text] [Related]
19. Pricing pharmaceutical compounds under development.
Dimitri N
Trends Pharmacol Sci; 2014 May; 35(5):217-8. PubMed ID: 24439477
[No Abstract] [Full Text] [Related]
20. Biotechnology partnerships--medicine for an ailing industry?
DeLamarter J
Nat Biotechnol; 2003 Aug; 21(8):847-8. PubMed ID: 12894192
[No Abstract] [Full Text] [Related]
[Next] [New Search]
